LY2523355

DRUG7 trials

Sponsors

Eli Lilly and Company, Kyowa Kirin Co., Ltd.

Conditions

Acute LeukemiaAdvanced CancerCancer of Head and NeckColorectal CancerEsophageal CancerGastric CancerMetastatic Breast CancerMetastatic Cancer

Phase 1

A Dose-Escalation Study for Patients With Advanced Cancer

CompletedNCT01214642

Eli Lilly and CompanyAdvanced Cancer

Start: 2008-05-31End: 2012-06-30Updated: 2018-08-06

A Study for Patients With Acute Leukemia

TerminatedNCT01214655

Eli Lilly and CompanyAcute Leukemia

Start: 2008-06-30End: 2011-02-28Updated: 2019-05-13

A Study for Participants With Advanced Cancer

CompletedNCT01214629

Eli Lilly and CompanyAdvanced Cancer, Metastatic Cancer

Start: 2007-07-31End: 2012-05-31Updated: 2018-08-06

A Study of LY2523355 in Patients With Solid Cancer

CompletedNCT01358019

Kyowa Kirin Co., Ltd.Solid Tumors

Start: 2011-05-31End: 2013-01-31Updated: 2013-01-28

Phase 2

A Study for Participants With Small-Cell Lung Cancer

CompletedNCT01025284

Eli Lilly and CompanySmall Cell Lung Cancer

Start: 2009-12-31End: 2012-07-31Updated: 2019-09-17

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

CompletedNCT01059643

Eli Lilly and CompanyCancer of Head and Neck, Colorectal Cancer, Esophageal Cancer +4

Start: 2011-04-30End: 2012-12-31Updated: 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

CompletedNCT01416389

Eli Lilly and CompanyMetastatic Breast Cancer

Start: 2011-08-31End: 2013-09-30Updated: 2019-09-18